Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Open, Randomized, Active Comparator-controlled, Multi-Center Study to Evaluate Safety and Efficacy of IBsolvMIR® in Islet Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03867851
• Other study ID #: NNCIT-02
• Status: Terminated
• Phase: Phase 2
• Start date: February 8, 2021
• Est. completion date: May 13, 2024

Study information

• Verified date: May 2024
• Source: TikoMed AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II open, randomized, active comparator-controlled multi center study in patients with severe type-1 diabetes. This is a two-armed study where patients are randomized in a 2:1 ratio between IBsolvMIR and heparin. Eighteen patients are planned to be included.

The study consists of up to 8 visits; screening, transplantation surgery with bolus administration of study drug or active comparator, IBsolvMIR doses on day 1, 3 and 6 after surgery, follow up visits on day 7 and 14, and follow-up phone call on day 44.

The primary endpoint is to study AEs up to 44 days following study drug administration. The secondary endpoints are to evaluate changes in TAT, C-peptide, C3a and HGF at baseline and during the first 24 hours after study drug administration, as well as evaluate a change in levels of C-peptide-glucose-creatinine ratio on day 14 compared to baseline.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: May 13, 2024
• Est. primary completion date: May 13, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patient on a waiting list for islet transplantation

2. Male and female patients age 18 to 60 years of age.

3. Ability to understand and provide written informed consent.

4. Mentally stable and able to comply with the procedures of the study protocol.

5. Clinical history compatible with type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years at the time of enrolment.

6. Documented C-peptide <0.1 nmol/L before first islet transplantation (stimulated in response to a MMTT or other confirmatory method).

7. All subjects must have received medical treatment of their diabetes under the guidance from an experienced endocrinologist. If not previously transplanted the patient must also have;

8. At least one episode of severe hypoglycemia in the past 1 year defined as an event with at least one of the following symptoms; memory loss, confusion, uncontrollable behavior, unusual difficulty in awakening, suspected seizure, loss of consciousness, or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood/plasma glucose level < 54 mg/dl [3.0 mmol/L] or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration OR

9. Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more.

Exclusion Criteria:

1. Patients with prior organ transplants other than a kidney graft and/or islets. A previous pancreas transplant can be accepted if it failed within the first week due to thrombosis and the graft was removed.

2. Patients with body mass index (BMI) > 30.

3. Insulin requirement > 0.7 Unit/kg/day at screening.

4. Consistently abnormal liver function tests (> 1.5 x ULN on two consecutive measurements > 2 weeks apart) at screening.

5. Proliferative untreated diabetic retinopathy

6. Increased risk for thrombosis (ex. homozygous APC-resistance) or bleeding (INR>1.5)

7. Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin

8. Patients with increased cardiac risk defined as;

• unstable coronary artery disease requiring hospitalization or revascularization within 6 months prior to baseline visit

• chronic heart failure which required hospitalization 30 days prior to baseline visit

9. Patients with active infections, unless treatment is not judged necessary by the investigators

10. Patients with serological evidence of infection with HIV, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.

11. Patients with active peptic ulcer disease, symptomatic gallstones or portal hypertension.

12. Patients who are pregnant or breastfeeding, or who intend to become pregnant.

13. Patients of childbearing potential not willing to use adequate double contraception with < 1% failure rate after the screening visit until the last visit.

14. Active alcohol or substance abuse

15. Patients with evidence of high-level sensitization (PRA> 50% with flow cytometry).

16. Patients with psychological conditions that make it unsafe to undergo islet transplantation or which preclude compliance with prescribed therapy

17. HbA1c > IFCC 100 mmol/mol, at screening.

18. Patients with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo treatment with IBsolvMIR.

19. Patients participating in or having participated in any other clinical drug studies in the past four weeks.

20. History of bleeding disorders

21. History of severe hypersensitivity

22. Previous known heparin-induced thrombocytopenia (HIT)

23. Patients with severe hepatic or renal impairment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1

Intervention

Drug:
• IBsolvMIR
Study drug IBsolvMIR
• Heparin
Clinical praxis

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Center	Leiden	Zuid-Holland
Norway	Oslo Universitetssykehus HF	Oslo
Sweden	Sahlgrenska sjukhuset	Göteborg
Sweden	Karolinska Universitetssjukhuset Huddinge	Stockholm
Sweden	Akademiska sjukhuset	Uppsala

Sponsors (1)

Lead Sponsor	Collaborator
TikoMed AB

Countries where clinical trial is conducted

Netherlands,  Norway,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bleeding events	Bleeding events after islet transplantation with total dose of 27 mg/kg BW IBsolvMIR in comparison to active comparator Heparin	Up to 44 days.
Primary	Other AEs/SAEs after islet transplantation	Other AEs/SAEs after islet transplantation with total dose of 27 mg/kg BW IBsolvMIR in comparison to active comparator Heparin	Up to 44 days.
Secondary	Difference between groups in levels of biomarkers	Difference between groups in levels of biomarkers after transplantation	Within 7 days.
Secondary	Change in C-peptide / (glucose x creatinine) ratio (CPGCR)	Change in CPGCR at day 14 compared to baseline.; CPGCR is calculated by: C-peptide (ng/mL) / ( glucose (mg/dL) x creatinine ratio (mg/dL) )	Within 14 days.